DBV Technologies | DBVT - Selling And Administration Expenses


DBV Technologies reported $15.8M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Amarin USD 18.97M 1.03M Dec/2025
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
DBV Technologies USD 15.8M 2.4M Sep/2026
Galectin Therapeutics USD 1.48M 110K Jun/2024
Halozyme Therapeutics USD 58.24M 1.24M Sep/2026
Incyte USD 364.27M 12.54M Sep/2026
Insmed USD 253.03M 5.56M Sep/2026
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
United Therapeutics USD 184.1M 22.6M Sep/2026